Reuters -- Roche Holding AG named the architect of its integration plan with Genentech to head the Swiss group’s dominant drugs business, putting the finishing touches to this spring’s $47 billion buyout of the U.S. biotech firm.
Reuters -- Roche Holding AG named the architect of its integration plan with Genentech to head the Swiss group’s dominant drugs business, putting the finishing touches to this spring’s $47 billion buyout of the U.S. biotech firm.
